Tutorials
NAS:TBPH (Cayman Islands)  
Theravance Biopharma Inc logo

Theravance Biopharma Inc

$ 9.61 +0.15 (+1.59%) 08:09 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 734.47M
Enterprise V:
$ 1.27B
Volume:
646.00K
Avg Vol (2M):
1.18M
Also Trade In:
Volume:
646.00K
Market Cap $:
734.47M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.18M
Enterprise Value $:
1.27B
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Theravance Biopharma Inc
NAICS : 325412 SIC : 2834
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Name Current Vs Industry Vs History
Cash-To-Debt 0.2
Equity-to-Asset -0.97
Debt-to-Equity -1.94
Debt-to-EBITDA -15.08
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.16
Distress
Grey
Safe
Beneish M-Score -2.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 70.38
9-Day RSI 62.08
14-Day RSI 58.12
6-1 Month Momentum % -5.54
12-1 Month Momentum % -34.78

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.74
Quick Ratio 4.74
Cash Ratio 4.07
Days Sales Outstanding 90.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.2

Financials (Next Earnings Date:2022-11-03 Est.)

TBPH's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:TBPH

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 52.386
EPS (TTM) ($) -1.36
Beta 0.42
Volatility % 57.29
14-Day RSI 58.12
14-Day ATR ($) 0.485893
20-Day SMA ($) 9.1645
12-1 Month Momentum % -34.78
52-Week Range ($) 6.1 - 14.28
Shares Outstanding (Mil) 76.43

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Theravance Biopharma Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More